Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

BAP1 Immunohistochemistry And P16 FISH To Separate Benign From Malignant Mesothelial Proliferations

B. Sheffield, H. Hwang, A. Lee, K. Thompson, S. Rodriguez, Christopher H Tse, A. Gown, A. Churg
Published 2015 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
A variety of immunohistochemical (IHC) stains have been proposed to mark either benign or malignant mesothelial proliferations. Loss of the p16 tumor suppressor (CDKN2A), through homozygous deletions of 9p21, is a good marker of mesotheliomas but lacks sensitivity. Recent reports indicate that some mesotheliomas are associated with loss of BRCA-associated protein 1 (BAP1) expression. Here we investigate BAP1 and p16 as potential markers of malignancy and compare test characteristics with previously proposed markers using a well-characterized tissue microarray. BAP1 protein expression was interrogated by IHC. The p16 locus was examined by fluorescence in situ hybridization (FISH) directed toward chromosome 9p21. Loss of BAP1 was identified in 7/26 mesotheliomas and 0/49 benign proliferations. Loss of p16 was identified in 14/27 mesotheliomas and 0/40 benign proliferations, yielding 100% specificity and positive predictive value for each marker. Together, BAP1 IHC and p16 FISH were 58% sensitive for detecting malignancy. Various combinations of p53, EMA, IMP3, and GLUT1 showed reasonably high specificity (96% to 98%) but poor to extremely poor sensitivity. Combined BAP1 IHC/p16 FISH testing is a highly specific method of diagnosing malignant mesotheliomas when the question is whether a mesothelial proliferation is benign or malignant and is particularly useful when tissue invasion by mesothelial cells cannot be demonstrated. However, combined BAP1/p16 FISH testing is not highly sensitive, and negative results do not rule out a mesothelioma. The test characteristics of previously proposed markers EMA, p53, GLUT1, IMP3 suggest that, even in combination, these markers are not useful tools in this clinical setting.
This paper references
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations
A. Lee (2013)
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations
M. Zauderer (2013)
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high‐risk area
M. Betti (2015)
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi (2012)
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
p16 Deletion in sarcomatoid tumors of the lung and pleura.
N. Tochigi (2013)
Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation
M. Shi (2011)
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
M. Ladanyi (2005)
[Guidelines for pathologic diagnosis of malignant mesothelioma--2012 update of the consensus statement from the International Mesothelioma Interest Group].
Riping Chen (2015)
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
Catherine T Chung (2010)
BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma
Akeesha A. Shah (2013)
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma
H. Hwang (2014)
BAP 1 protein loss by immunohistochemistry : a potentially useful tool for prognostic prediction in patients with uveal melanoma Pathology
AA Shah (2013)
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma
Y. Kato (2007)
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low‐risk clear cell renal cell carcinoma
R. Joseph (2014)
Tumours associated with BAP1 mutations
R. Murali (2013)
p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
P. Cagle (1994)
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
S. Monaco (2011)
Germline BAP1 mutations predispose also to multiple basal cell carcinomas
A. de la Fouchardière (2015)
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
Germline BAP1 mutations predispose also to basal cell carcinomas
A De la Fouchardiere (2014)
Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma
Anna E. Koopmans (2014)
Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing
H. Kalirai (2014)
The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment
A. Battaglia (2014)
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports
J. King (2006)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)

This paper is referenced by
Cytological diagnosis of malignant pleural mesothelioma
S. M. Chai (2017)
Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
A. Churg (2018)
Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations.
B. Sheffield (2016)
Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples
S. Monaco (2018)
Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
Michael Zaleski (2020)
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells
Y. Takehara (2018)
Current applications of molecular testing on body cavity fluids.
D. Pinto (2020)
Pathology International
S. Noriki (2019)
Young investigator challenge: MicroRNA‐21/MicroRNA‐126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology
R. Cappellesso (2016)
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
A. Nicholson (2019)
Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.
L. Brcic (2018)
BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
Stephanie M. McGregor (2015)
Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma
Raghavendra Pillappa (2018)
The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma
A. Singhi (2016)
Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms.
J. Woo (2017)
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests
T. Hida (2016)
Morphological difference between pleural mesothelioma cells in effusion smears with either BAP1 loss or 9p21 homozygous deletion and reactive mesothelial cells without the gene alterations
S. Matsumoto (2019)
Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Fabien Forest (2018)
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center
F. Sallé (2018)
Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.
J. Andrici (2016)
Loss of BRCA1‐associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions
I. Cozzi (2018)
A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions
P. Desmeules (2017)
Pathological Diagnosis of Mesothelioma
G. Fontanini (2019)
Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
J. Andrici (2015)
Distant Cutaneous Metastasis Of Malignant Epithelioid Mesothelioma.
Katrina Collins (2020)
Apport de l’expression protéique de BRCA1 associated protein 1 (BAP1) dans le diagnostic des mésothéliomes malins diffus pleuraux : une analyse cytologique et histologique comparative sur une série de 50 patients
A. Jaouen (2016)
Analysis of YAP1 and TAZ expression by immunohistochemical staining in malignant mesothelioma and reactive mesothelial cells
Y. Takehara (2018)
Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X
N. Joseph (2017)
Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
Yoshiaki Kinoshita (2020)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
Gamze Kulduk (2019)
Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma
A. Shinozaki-Ushiku (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar